公开(公告)号：US20050288573A1

公开(公告)日：2005-12-29

申请号：US11142631

申请日：2005-06-01

Applicant: Graham Timmins

Inventor： Graham Timmins

IPC: A61B5/05 ,  A61B5/055 ,  A61B5/103

CPC classification number: A61B5/415 ,  A61B5/055 ,  A61B5/418 ,  A61B5/441 ,  G01R33/60

Abstract: Embodiments of methods and apparatus use electron paramagnetic resonance spectroscopy to provide a signal from melanin to image a melanoma. Embodiments of methods and apparatus use electron paramagnetic resonance spectroscopy to provide a signal from melanin to detect metastatic melanoma in a sentinel lymph node. Embodiments of methods and apparatus use electron paramagnetic resonance spectroscopy to provide a signal from melanin to measure light penetration in melanocytes in skin.

Abstract translation: 方法和装置的实施方案使用电子顺磁共振光谱法来提供来自黑色素的信号以成像黑素瘤。 方法和装置的实施例使用电子顺磁共振光谱法来提供来自黑色素的信号以检测前哨淋巴结中的转移性黑素瘤。 方法和装置的实施方案使用电子顺磁共振光谱法来提供来自黑色素的信号以测量皮肤中黑素细胞中的光穿透。

公开(公告)号：US20210128527A1

公开(公告)日：2021-05-06

申请号：US16770438

申请日：2018-12-07

Applicant: Graham Timmins ,  Ke Jian Liu ,  Rong Pan ,  UNM Rainforest Innovations

Inventor： Graham Timmins ,  Ke Jian Liu ,  Rong Pan

IPC: A61K31/409 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/4706 ,  A61K31/496 ,  A61K31/437 ,  A61P9/10

Abstract: A pharmaceutical composition includes a ferrochelatase inhibitor and a pharmaceutically acceptable carrier. In another aspect, a method of treating a subject having, or a t risk of having, a hemorrhagic stroke generally includes administering to the subject a pharmaceutical composition that includes a ferrochelatase inhibitor in an amount effective to ameliorate at least one symptom or clinical sign of hemorrhagic stroke.

公开(公告)号：US09599625B2

公开(公告)日：2017-03-21

申请号：US14325126

申请日：2014-07-07

Applicant: Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

Inventor： Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4703 ,  G01N2800/2871 ,  G01N2800/52

Abstract: Methods and apparatus for determining blood brain barrier (BBB) damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample.

公开(公告)号：US20150198617A1

公开(公告)日：2015-07-16

申请号：US14677053

申请日：2015-04-02

Applicant: Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

Inventor： Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4703 ,  G01N2800/2871 ,  G01N2800/52

Abstract: Methods and apparatus for determining blood brain barrier (BBB) damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample.

Abstract translation: 提供了用于确定血脑屏障（BBB）损伤并治疗可能由于缺血事件而遭受BBB损伤的患者的方法和装置。 所述方法和装置涉及检测血液样品中裂解的闭合蛋白片段的存在。 根据一些实施方案，该方法进一步提供基于样品中闭合蛋白片段的浓度确定BBB损伤的程度。 在进一步的实施方案中，本公开提供用于检测血液样品中闭合蛋白片段的存在的试剂盒。

公开(公告)号：US20140314737A1

公开(公告)日：2014-10-23

申请号：US14325126

申请日：2014-07-07

Applicant: Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

Inventor： Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4703 ,  G01N2800/2871 ,  G01N2800/52

Abstract: Methods and apparatus for determining blood brain barrier (BBB) damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample.

Abstract translation: 提供了用于确定血脑屏障（BBB）损伤并治疗可能由于缺血事件而遭受BBB损伤的患者的方法和装置。 所述方法和装置涉及检测血液样品中裂解的闭合蛋白片段的存在。 根据一些实施方案，该方法进一步提供基于样品中闭合蛋白片段的浓度确定BBB损伤的程度。 在进一步的实施方案中，本公开提供用于检测血液样品中闭合蛋白片段的存在的试剂盒。

公开(公告)号：US07897400B2

公开(公告)日：2011-03-01

申请号：US11955773

申请日：2007-12-13

Applicant: Graham Timmins ,  Vojo P. Deretic

Inventor： Graham Timmins ,  Vojo P. Deretic

IPC: G01N33/00 ,  A61K31/44

CPC classification number: A61B5/0002 ,  A61B5/082 ,  A61B5/411 ,  A61B5/415 ,  A61B5/416 ,  A61B5/418 ,  A61K49/0004 ,  G01N33/5695

Abstract: This invention relates to a test for detecting a Mycobacterium tuberculosis (tuberculosis or TB) infection in a patient or subject, specifically a diagnostic test, including a breath test, whereby patients are provided a small dose of an isotopically labeled TB drug, Isoniazid (INH) orally or directly to the lungs of the patient or subject. If TB is present, a TB enzyme mycobacterial peroxidase KatG oxidizes the INH; and KatG specific metabolites, in particular, isotopically labeled nitric oxide (NO), nitrites, nitrates, carbon monoxide (CO) or carbon dioxide converted from carbon monoxide of INH cleavage are measured. Other embodiments relate to a diagnostic breath test for detecting TB utilizing isotopically labeled urea (preferably, carbon-13 labeled urea), alone or in combination with isotopically labeled isoniazid (preferably, nitrogen-15 labeled isoniazid), wherein M. tuberculosis organism, if present in the patient or subject's lungs (or other tissues), will metabolize the isotopically labeled urea to isotopically labeled carbon dioxide (CO2) such that a determination of the residence of M. tuberculosis, including residence of an isoniazid resistant strain of M. tuberculosis, may be made.

Abstract translation: 本发明涉及一种用于检测患者或受试者中结核分枝杆菌（结核病或结核病）感染的试验，特别是包括呼吸试验的诊断试验，其中向患者提供小剂量的同位素标记的结核病药物异烟肼（INH ）口服或直接给予患者或受试者的肺。 如果TB存在，TB酶分枝杆菌过氧化物酶KatG氧化INH; 并测定KatG特异性代谢物，特别是同位素标记的一氧化氮（NO），亚硝酸盐，硝酸盐，一氧化碳（CO）或由INH切割的一氧化碳转化的二氧化碳。 其他实施方案涉及用于使用同位素标记的尿素（优选碳-13标记的尿素）单独或与同位素标记的异烟肼（优选氮-15标记的异烟肼）组合来检测结核病的诊断性呼吸试验，其中结核分枝杆菌生物体如果 存在于患者或受试者的肺部（或其他组织）中，将同位素标记的尿素代谢为同位素标记的二氧化碳（CO 2），从而确定结核分枝杆菌的住所，包括结核分枝杆菌的异烟肼抗性菌株的停留 ，可以做。

公开(公告)号：US20080305050A1

公开(公告)日：2008-12-11

申请号：US12150199

申请日：2008-04-25

Applicant: Graham Timmins ,  Vojo P. Deretic

Inventor： Graham Timmins ,  Vojo P. Deretic

IPC: A61K8/40 ,  G01N33/554 ,  A61K31/17 ,  A61K31/195 ,  A61K33/00

CPC classification number: C12Q1/04 ,  A61K51/04 ,  A61K51/0406 ,  A61K51/1206 ,  G01N33/497 ,  G01N2333/21

Abstract: The present invention relates to methods for detecting P aeruginosa infection and bacterial burden in the lungs of patients who are at risk for P. aeruginosa infections, especially including patients with Cystic Fibrosis (CF). The present method provides numerous tests (breath, blood, urine) which are readily administered to a patient that will sensitively and specifically detect the presence and extent of lung infection P. aeruginosa (both mucoid and non-mucoid), and allow monitoring of bacterial load as a parameter in monitoring treatment.

Abstract translation: 本发明涉及用于检测铜绿假单胞菌感染风险的患者肺部铜绿假单胞菌感染和细菌负担的方法，特别是包括囊性纤维化（CF）患者。 本方法提供了许多试验（呼吸，血液，尿液），其易于对患者施用，其将敏感且特异性地检测肺部感染铜绿假单胞菌（粘液样和非粘液样）的存在和程度，并允许监测细菌 负载作为监测治疗的参数。